Kezar Life Sciences, Inc.KZRNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +0.39% | -89.96% | -89.96% | -89.97% | -89.96% |
| Weighted Average Shares Diluted Growth | +0.39% | -89.96% | -89.96% | -89.97% | -89.96% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -84.44% | -81.49% | -28.02% | +18.33% | +83.84% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -34.19% | -34.60% | -37.10% | -39.35% | -40.44% |
| Book Value per Share Growth | -38.18% | +521.07% | +507.30% | +507.21% | +516.73% |
| Debt Growth | -13.52% | -14.54% | -22.84% | -31.44% | -41.39% |
| R&D Expense Growth | -31.58% | -29.20% | -29.07% | -41.20% | -57.43% |
| SG&A Expenses Growth | -35.08% | +1.19% | -13.22% | -10.48% | -19.84% |